Lipoprotein(a) and thromboembolism: current state of knowledge and unsolved issues
Małgorzata Konieczyńska, Joanna Natorska, Michał Ząbczyk, Anetta Undas · 2024
Read Lipoprotein(a) and thromboembolism: current state of knowledge and unsolved issues by Małgorzata Konieczyńska, Joanna Natorska, Michał Ząbczyk, Anetta Undas (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11831339.txt.
Description
Małgorzata Konieczyńska, Joanna Natorska, Michał Ząbczyk, and Anetta Undas review what is known about lipoprotein(a) and blood clots, in a paper from twenty twenty-four. Lipoprotein(a) is set by genes and is a risk factor for heart and vessel disease. High levels affect about a fifth of Europeans. Its role in venous clots, though, remains in doubt.
The strongest proof supports an antifibrinolytic action. The particle blocks plasminogen activation and so slows clot breakdown. Smaller forms of its key protein are the most potent. Other paths include denser fibrin networks, platelet activation, and inflammation from oxidized phospholipids. Clots in odd sites, like cerebral and retinal veins, are discussed too. New lipoprotein(a)-lowering drugs are now in randomized trials. They might also cut clot risk, an open point the authors flag.
Catalog record
| CREATOR | Małgorzata Konieczyńska, Joanna Natorska, Michał Ząbczyk, Anetta Undas |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |